Why GSK’s Shingrix still sets the pace in shingles prevention

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 09:08. Details in the imprint.

With Shingrix, GSK wants to spare adults the sharp, burning jolt of shingles that can turn a normal day into a pain marathon. The recombinant vaccine targets older and immunocompromised adults who dread post-herpetic neuralgia as much as the rash itself.

Who Shingrix is for

Shingrix is designed for adults from 50 years and for certain immunocompromised patients from 18 years, depending on local approvals. It targets herpes zoster, the reactivation of varicella-zoster virus that once caused chickenpox and now hides in nerve roots.

In everyday practice, doctors usually offer Shingrix as a planned protection step, often during routine check-ups. Patients who have seen relatives suffer from post-herpetic neuralgia tend to be especially motivated to complete the two-dose schedule.

How the vaccine works in the body

Unlike the older live-attenuated shingles vaccine, Shingrix uses a non-live recombinant glycoprotein E antigen combined with the AS01B adjuvant system to trigger a strong cellular and humoral immune response. The EMA’s assessment report details this antigen-adjuvant combination.

That design is meant to be especially helpful for older immune systems, which typically react more sluggishly to vaccines. In trials, this approach has translated into robust protection even in patients aged 70 and above over several years.

Efficacy and protection duration

In pivotal phase 3 studies, Shingrix showed around 97 percent efficacy against shingles in people aged 50 and over and about 91 percent in those 70 and above at first analysis. Data published in the New England Journal of Medicine describe these trial results.

Longer-term follow-up suggests that protection remains high for at least ten years, which matters for public-health planners considering broad vaccination programs. For everyday users, this means fewer worries about a painful shingles episode late in life.

Dosing, side effects, daily experience

The standard regimen for Shingrix is two intramuscular injections given two to six months apart, usually in the upper arm. Completing both doses is important, so pharmacies and clinics often remind patients actively to come back.

Injection-site pain, fatigue, muscle aches, and mild fever are very common in the first days after vaccination and can feel quite intense for some, almost like a short, raw flu. GSK’s European approval announcement highlights this reactogenic profile.

Pricing and availability

List prices differ widely by market, but in the US Shingrix often has a list price of a few hundred dollars for the full two-dose course before insurance. Many national health systems in Europe reimburse Shingrix partially or fully for defined risk groups.

In Germany, for example, the Standing Committee on Vaccination (STIKO) recommends Shingrix for adults 60 and older and from 18 years with certain underlying conditions, and statutory health insurers usually cover the cost. Availability is via general practitioners and vaccination clinics.

What it means for GSK

Shingrix has become one of GSK’s flagship vaccines, with the company repeatedly pointing to strong demand in Europe, North America, and expanding markets in Asia. For GSK’s vaccines portfolio, it provides a predictable, recurring revenue stream with demographic tailwind.

GSK plc shares (ISIN GB0009252882) trade primarily on the London Stock Exchange in pounds sterling as part of the FTSE 100 index.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.